The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:2999382 48 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program. Methods: The program is open for laboratories using commercially available kits for Aβ, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Mölndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples. Results: Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure Aβ-(1-42), P-tau(181P), and T-tau), and 5 used Meso Scale Discovery with the Aβ triplex (AβN-42, AβN-40, and AβN-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories. Conclusions: Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers. © 2011 The Alzheimer's Association. All rights reserved.
Έτος δημοσίευσης:
2011
Συγγραφείς:
Mattsson, N.
Andreasson, U.
Persson, S.
Arai, H.
Batish, S.D.
Bernardini, S.
Bocchio-Chiavetto, L.
Blankenstein, M.A.
Carrillo, M.C.
Chalbot, S.
Coart, E.
Chiasserini, D.
Cutler, N.
Dahlfors, G.
Duller, S.
Fagan, A.M.
Forlenza, O.
Frisoni, G.B.
Galasko, D.
Galimberti, D.
Hampel, H.
Handberg, A.
Heneka, M.T.
Herskovits, A.Z.
Herukka, S.-K.
Holtzman, D.M.
Humpel, C.
Hyman, B.T.
Iqbal, K.
Jucker, M.
Kaeser, S.A.
Kaiser, E.
Kapaki, E.
Kidd, D.
Klivenyi, P.
Knudsen, C.S.
Kummer, M.P.
Lui, J.
Lladó, A.
Lewczuk, P.
Li, Q.-X.
Martins, R.
Masters, C.
McAuliffe, J.
Mercken, M.
Moghekar, A.
Molinuevo, J.L.
Montine, T.J.
Nowatzke, W.
O'Brien, R.
Otto, M.
Paraskevas, G.P.
Parnetti, L.
Petersen, R.C.
Prvulovic, D.
De Reus, H.P.M.
Rissman, R.A.
Scarpini, E.
Stefani, A.
Soininen, H.
Schröder, J.
Shaw, L.M.
Skinningsrud, A.
Skrogstad, B.
Spreer, A.
Talib, L.
Teunissen, C.
Trojanowski, J.Q.
Tumani, H.
Umek, R.M.
Van Broeck, B.
Vanderstichele, H.
Vecsei, L.
Verbeek, M.M.
Windisch, M.
Zhang, J.
Zetterberg, H.
Blennow, K.
Περιοδικό:
American Journal of Alzheimer's Disease and other Dementias
Εκδότης:
ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
Τόμος:
7
Αριθμός / τεύχος:
4
Σελίδες:
386-395.e6
Λέξεις-κλειδιά:
amyloid beta protein; phosphorylated tau; tau protein; unclassified drug, Alzheimer disease; article; cerebrospinal fluid; disease marker; health program; laboratory diagnosis; measurement; priority journal; quality control
Επίσημο URL (Εκδότης):
DOI:
10.1016/j.jalz.2011.05.2243
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.